Walder Wyss with Fielmann as Zeiss buys 10% in Ocumenda
Walder Wyss advised Fielmann Group and tele-ophthalmology platform Ocumeda, as the the first agreed to sell a 10% stake in Ocumenda to Zeiss Vision Care. The deal implied a total company valuation of EUR 100m, with the intention from the buyer to extend the investment up to a 25% stake.
The Walder Wyss team
Walder Wyss’ partner Robert von Rosen (corporate/M&A, pictured) led the operation, together with Fielmann’s Group General Counsel Fabian Walla. The Walder Wyss team further comprised partner Monique Sturny (competition), partner Marius Breier (tax), senior associate Christoph Burkhardt (corporate/M&A), managing associate Vangelis Kalaitzidakis (tax), associate Oerjan Wickart (corporate/M&A), associate Johannes Stamm (competition) and associate Lorenzo Petrone (corporate/M&A).
